Manila Times Business
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Over 300 non-resident Filipinos, govt, civic leaders gather for diaspora summit
Just now
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
Just now
Doing Good Index 2026: Asia’s US$753 Billion Philanthropic Potential Remains Unrealized
Just now
Quest Global Launches Neprion to Accelerate AI Smart Wearables Launch Readiness
Just now